Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction a TIMI 14 substudy

C. Michael Gibson, James A de Lemos, Sabina A. Murphy, Susan J. Marble, Carolyn H. McCabe, Christopher P. Cannon, Elliott M. Antman, Eugene Braunwald

Research output: Contribution to journalArticle

302 Citations (Scopus)

Abstract

Background - Use of abciximab in combination with administration of thrombolytics has been shown to improve epicardial and microvascular coronary blood flow in acute myocardial infarction (AMI). As a potential mechanism, we hypothesized that combination therapy would reduce angiographically evident thrombus (AET) and would increase lumen diameter compared with thrombolytic monotherapy. Methods and Results - Patients who received combination therapy in TIMI 14 (low-dose thrombolytic plus abciximab, n=732) were compared with patients who received thrombolytic monotherapy without abciximab in the TIMI 4, 10A, 10B, and 14 trials (n=1662). Thrombus burden was assessed 90 minutes after treatment, and quantitative angiography was performed in an angiographic core laboratory by investigators blinded to treatment assignment. The frequency of AET was reduced in patients who received abciximab combination therapy compared with thrombolytic monotherapy (26.6% versus 35.4%, P<0.001). Similar findings were observed when the analysis was restricted to patients with patent arteries (14.7% versus 20.8%, P=0.001). Residual percent diameter stenosis at 90 minutes was also improved in the abciximab therapy group both in patent arteries (64.6±16.6 versus 68.3±14.8, P<0.001) and between patent and occluded arteries (69.3±19.5 versus 73.8±17.9, P<0.001). The absence of AET was associated with an increased frequency of >70% ST-segment resolution by 90 minutes (37.2%, 110/296 versus 18.9%, 54/286, P<0.001). Conclusions - Compared with thrombolytic monotherapy, combination therapy with abciximab reduces AET, which in turn is associated with reduced residual stenosis and improved ST-segment resolution in AMI. These data provide a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMI.

Original languageEnglish (US)
Pages (from-to)2550-2554
Number of pages5
JournalCirculation
Volume103
Issue number21
StatePublished - May 29 2001

Fingerprint

Thrombosis
Myocardial Infarction
Therapeutics
abciximab
Angiography
Pathologic Constriction
Blood Platelets
Perfusion
Research Personnel

Keywords

  • Abciximab
  • Blood flow
  • Myocardial infarction
  • Thrombolysis
  • Thrombus

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Gibson, C. M., de Lemos, J. A., Murphy, S. A., Marble, S. J., McCabe, C. H., Cannon, C. P., ... Braunwald, E. (2001). Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction a TIMI 14 substudy. Circulation, 103(21), 2550-2554.

Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction a TIMI 14 substudy. / Gibson, C. Michael; de Lemos, James A; Murphy, Sabina A.; Marble, Susan J.; McCabe, Carolyn H.; Cannon, Christopher P.; Antman, Elliott M.; Braunwald, Eugene.

In: Circulation, Vol. 103, No. 21, 29.05.2001, p. 2550-2554.

Research output: Contribution to journalArticle

Gibson, CM, de Lemos, JA, Murphy, SA, Marble, SJ, McCabe, CH, Cannon, CP, Antman, EM & Braunwald, E 2001, 'Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction a TIMI 14 substudy', Circulation, vol. 103, no. 21, pp. 2550-2554.
Gibson, C. Michael ; de Lemos, James A ; Murphy, Sabina A. ; Marble, Susan J. ; McCabe, Carolyn H. ; Cannon, Christopher P. ; Antman, Elliott M. ; Braunwald, Eugene. / Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction a TIMI 14 substudy. In: Circulation. 2001 ; Vol. 103, No. 21. pp. 2550-2554.
@article{d751a289c2f0436ab5cd2b9f21b5eaa2,
title = "Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction a TIMI 14 substudy",
abstract = "Background - Use of abciximab in combination with administration of thrombolytics has been shown to improve epicardial and microvascular coronary blood flow in acute myocardial infarction (AMI). As a potential mechanism, we hypothesized that combination therapy would reduce angiographically evident thrombus (AET) and would increase lumen diameter compared with thrombolytic monotherapy. Methods and Results - Patients who received combination therapy in TIMI 14 (low-dose thrombolytic plus abciximab, n=732) were compared with patients who received thrombolytic monotherapy without abciximab in the TIMI 4, 10A, 10B, and 14 trials (n=1662). Thrombus burden was assessed 90 minutes after treatment, and quantitative angiography was performed in an angiographic core laboratory by investigators blinded to treatment assignment. The frequency of AET was reduced in patients who received abciximab combination therapy compared with thrombolytic monotherapy (26.6{\%} versus 35.4{\%}, P<0.001). Similar findings were observed when the analysis was restricted to patients with patent arteries (14.7{\%} versus 20.8{\%}, P=0.001). Residual percent diameter stenosis at 90 minutes was also improved in the abciximab therapy group both in patent arteries (64.6±16.6 versus 68.3±14.8, P<0.001) and between patent and occluded arteries (69.3±19.5 versus 73.8±17.9, P<0.001). The absence of AET was associated with an increased frequency of >70{\%} ST-segment resolution by 90 minutes (37.2{\%}, 110/296 versus 18.9{\%}, 54/286, P<0.001). Conclusions - Compared with thrombolytic monotherapy, combination therapy with abciximab reduces AET, which in turn is associated with reduced residual stenosis and improved ST-segment resolution in AMI. These data provide a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMI.",
keywords = "Abciximab, Blood flow, Myocardial infarction, Thrombolysis, Thrombus",
author = "Gibson, {C. Michael} and {de Lemos}, {James A} and Murphy, {Sabina A.} and Marble, {Susan J.} and McCabe, {Carolyn H.} and Cannon, {Christopher P.} and Antman, {Elliott M.} and Eugene Braunwald",
year = "2001",
month = "5",
day = "29",
language = "English (US)",
volume = "103",
pages = "2550--2554",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "21",

}

TY - JOUR

T1 - Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction a TIMI 14 substudy

AU - Gibson, C. Michael

AU - de Lemos, James A

AU - Murphy, Sabina A.

AU - Marble, Susan J.

AU - McCabe, Carolyn H.

AU - Cannon, Christopher P.

AU - Antman, Elliott M.

AU - Braunwald, Eugene

PY - 2001/5/29

Y1 - 2001/5/29

N2 - Background - Use of abciximab in combination with administration of thrombolytics has been shown to improve epicardial and microvascular coronary blood flow in acute myocardial infarction (AMI). As a potential mechanism, we hypothesized that combination therapy would reduce angiographically evident thrombus (AET) and would increase lumen diameter compared with thrombolytic monotherapy. Methods and Results - Patients who received combination therapy in TIMI 14 (low-dose thrombolytic plus abciximab, n=732) were compared with patients who received thrombolytic monotherapy without abciximab in the TIMI 4, 10A, 10B, and 14 trials (n=1662). Thrombus burden was assessed 90 minutes after treatment, and quantitative angiography was performed in an angiographic core laboratory by investigators blinded to treatment assignment. The frequency of AET was reduced in patients who received abciximab combination therapy compared with thrombolytic monotherapy (26.6% versus 35.4%, P<0.001). Similar findings were observed when the analysis was restricted to patients with patent arteries (14.7% versus 20.8%, P=0.001). Residual percent diameter stenosis at 90 minutes was also improved in the abciximab therapy group both in patent arteries (64.6±16.6 versus 68.3±14.8, P<0.001) and between patent and occluded arteries (69.3±19.5 versus 73.8±17.9, P<0.001). The absence of AET was associated with an increased frequency of >70% ST-segment resolution by 90 minutes (37.2%, 110/296 versus 18.9%, 54/286, P<0.001). Conclusions - Compared with thrombolytic monotherapy, combination therapy with abciximab reduces AET, which in turn is associated with reduced residual stenosis and improved ST-segment resolution in AMI. These data provide a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMI.

AB - Background - Use of abciximab in combination with administration of thrombolytics has been shown to improve epicardial and microvascular coronary blood flow in acute myocardial infarction (AMI). As a potential mechanism, we hypothesized that combination therapy would reduce angiographically evident thrombus (AET) and would increase lumen diameter compared with thrombolytic monotherapy. Methods and Results - Patients who received combination therapy in TIMI 14 (low-dose thrombolytic plus abciximab, n=732) were compared with patients who received thrombolytic monotherapy without abciximab in the TIMI 4, 10A, 10B, and 14 trials (n=1662). Thrombus burden was assessed 90 minutes after treatment, and quantitative angiography was performed in an angiographic core laboratory by investigators blinded to treatment assignment. The frequency of AET was reduced in patients who received abciximab combination therapy compared with thrombolytic monotherapy (26.6% versus 35.4%, P<0.001). Similar findings were observed when the analysis was restricted to patients with patent arteries (14.7% versus 20.8%, P=0.001). Residual percent diameter stenosis at 90 minutes was also improved in the abciximab therapy group both in patent arteries (64.6±16.6 versus 68.3±14.8, P<0.001) and between patent and occluded arteries (69.3±19.5 versus 73.8±17.9, P<0.001). The absence of AET was associated with an increased frequency of >70% ST-segment resolution by 90 minutes (37.2%, 110/296 versus 18.9%, 54/286, P<0.001). Conclusions - Compared with thrombolytic monotherapy, combination therapy with abciximab reduces AET, which in turn is associated with reduced residual stenosis and improved ST-segment resolution in AMI. These data provide a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMI.

KW - Abciximab

KW - Blood flow

KW - Myocardial infarction

KW - Thrombolysis

KW - Thrombus

UR - http://www.scopus.com/inward/record.url?scp=0035967494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035967494&partnerID=8YFLogxK

M3 - Article

C2 - 11382722

AN - SCOPUS:0035967494

VL - 103

SP - 2550

EP - 2554

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 21

ER -